Skip to main content
main-content

medwireNews@ESMO2017

Conference commentaries

20-09-2017 | ESMO 2017 | Video

ESMO 2017: Melanoma highlights

ESMO Melanoma Faculty Coordinator Olivier Michielin discusses the CheckMate 238, COMBI-AD, and BRIM8 trials presented at the third Presidential symposium.

15-09-2017 | ESMO 2017 | Video

NSCLC highlights from ESMO 2017

ESMO expert Floriana Morgillo provides independent comment on the PACIFIC, FLAURA, and IFCT-0302 trials, the focus of the first Presidential symposium.

15-09-2017 | ESMO 2017 | Video

Osimertinib: A potential new standard of care for advanced EGFR-mutated NSCLC

Suresh Ramalingam discusses the practice-changing results of the FLAURA study pitting osimertinib against gefitinib or erlotinib in the first-line advanced NSCLC setting.

14-09-2017 | ESMO 2017 | Video

CT timing questioned for patients after complete NSCLC resection

Virginie Westeel explains the results of the phase III IFCT-0302 trial examining the benefit of CT imaging in NSCLC patients who have undergone complete resection.

Research news

20-09-2017 | Epidemiology | ESMO 2017 | News

ESMO 2017 in brief

Cancer vigilance may be warranted for stroke survivors

Survivors of ischemic stroke are more likely to be diagnosed with cancer than the general population, a chart review suggests.

19-09-2017 | Risk factors | ESMO 2017 | News

ESMO 2017 in brief

Abdominal fat linked to elevated cancer risk

Central obesity is associated with an increased incidence of cancer in postmenopausal women, according to research presented at the ESMO 2017 Congress in Madrid, Spain.

18-09-2017 | Non-small cell lung cancer | ESMO 2017 | News

ESMO 2017

Dabrafenib–trametinib actively targets BRAF V600E-mutant metastatic NSCLC

Dabrafenib in combination with trametinib provides long-lasting antitumor activity in patients with previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer, with a tolerable safety profile, researchers report.

Source:

Lancet Oncol 2017; Advance online publication

15-09-2017 | Renal cell carcinoma | ESMO 2017 | News

ESMO 2017

Nivolumab–ipilimumab duo ‘a new standard of care’ in first-line advanced RCC

Phase III trial results presented at the ESMO 2017 Congress support the use of nivolumab plus ipilimumab for the first-line treatment of patients with advanced or metastatic clear-cell renal cell carcinoma.

15-09-2017 | Mesothelioma | ESMO 2017 | News

ESMO 2017 in brief

MAPS2 update supports checkpoint inhibition in relapsed malignant pleural mesothelioma

Treatment with checkpoint inhibitors could be an option for patients with relapsed malignant pleural mesothelioma, say the MAPS2 researchers who reported the survival data of patients given nivolumab alone and alongside ipilimumab.

14-09-2017 | Melanoma | ESMO 2017 | News

ESMO 2017

Adjuvant nivolumab improves RFS over ipilimumab in metastatic melanoma patients

Patients with resected stage IIIB–IV melanoma derive a significant recurrence-free survival benefit from adjuvant treatment with nivolumab versus ipilimumab, interim results from the CheckMate 238 trial indicate.

Source:

N Engl J Med 2017; Advance online publication

13-09-2017 | Cervical cancer | ESMO 2017 | News

ESMO 2017

Neoadjuvant chemotherapy approach fails to improve locally advanced cervical cancer survival

Concomitant chemoradiation remains the standard of care for women with locally advanced squamous carcinoma of the cervix, following research showing no significant survival advantage with chemotherapy followed by surgery.

12-09-2017 | Urothelial cancer | ESMO 2017 | News

ESMO 2017

Ramucirumab plus docetaxel prolongs PFS in advanced urothelial cancers

Adding ramucirumab to docetaxel significantly improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, show results from the phase III RANGE trial.

Source:

Lancet 2017; Advance online publication

12-09-2017 | Non-small cell lung cancer | ESMO 2017 | News

ESMO 2017

PACIFIC: Durvalumab prolongs PFS in stage III NSCLC patients

Consolidation treatment with the anti-programmed cell death ligand 1 antibody durvalumab improves progression-free survival in patients with stage III, locally advanced, inoperable non-small-cell lung cancer, shows the placebo-controlled PACIFIC trial.

Source:

N Engl J Med 2017; Advance online publication

12-09-2017 | Breast cancer | ESMO 2017 | News

ESMO 2017

First-line abemaciclib supported for HR+HER2– advanced breast cancer

Results from the MONARCH 3 study give support to first-line use of the oral selective CDK4/6 inhibitor abemaciclib, taken alongside nonsteroidal aromatase inhibitor therapy, in patients with advanced hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.

11-09-2017 | Melanoma | ESMO 2017 | News

ESMO 2017

Dabrafenib plus trametinib cuts melanoma relapse risk significantly

Adjuvant combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib halves the risk for relapse in patients with stage III melanoma with BRAF V600E or V600K mutations, show results from the COMBI-AD trial.

Source:

N Engl J Med 2017; Advance online publication

11-09-2017 | Glioblastoma multiforme | ESMO 2017 | News

ESMO 2017

Regorafenib improves outcomes in relapsed glioblastoma patients

The phase II REGOMA trial shows that patients with recurrent glioblastoma derive a significant overall survival and disease control benefit from treatment with regorafenib over lomustine.

11-09-2017 | Ovarian cancer | ESMO 2017 | News

ESMO 2017

ARIEL3 demonstrates maintenance rucaparib benefit for advanced platinum-sensitive ovarian cancer

Maintenance therapy with the PARP inhibitor rucaparib offers significantly longer progression-free survival than placebo for women with advanced platinum-sensitive ovarian cancer, indicate ARIEL3 trial findings reported at the ESMO 2017 Congress in Madrid, Spain.

Source:

Lancet 2017; Advance online publication

11-09-2017 | Ovarian cancer | ESMO 2017 | News

ESMO 2017

No PFS gain with dose-dense weekly chemotherapy in epithelial ovarian cancer

The 3-weekly regimen of carboplatin and paclitaxel should remain the first-line standard of care for women with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, say the ICON8 researchers who did not find a progression-free survival benefit with dose-dense weekly chemotherapy.

10-09-2017 | Non-small cell lung cancer | ESMO 2017 | News

ESMO 2017 in brief

Follow-up CT of ‘no benefit’ in the 2 years after complete NSCLC resection

Follow-up computed tomography imaging does not provide a clear survival benefit for patients who undergo complete resection of stage I–III non-small-cell lung cancer, suggests research presented at the ESMO 2017 Congress in Madrid, Spain.

09-09-2017 | Non-small cell lung cancer | ESMO 2017 | News

ESMO 2017 in brief

Osimertinib best in first-line advanced NSCLC setting

Osimertinib significantly improves outcomes relative to gefitinib or erlotinib in treatment-naïve patients with advanced epidermal growth factor receptor-mutated non-small-cell lung cancer, the phase III FLAURA trial shows.

image credits